Compare IGC & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IGC | PDSB |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 29.6M |
| IPO Year | 2005 | 2015 |
| Metric | IGC | PDSB |
|---|---|---|
| Price | $0.29 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.25 | ★ $9.00 |
| AVG Volume (30 Days) | 466.5K | ★ 943.8K |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.09 | 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,271,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $0.51 |
| 52 Week High | $0.50 | $1.90 |
| Indicator | IGC | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 53.41 |
| Support Level | $0.28 | $0.91 |
| Resistance Level | $0.31 | $1.44 |
| Average True Range (ATR) | 0.01 | 0.18 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 29.01 | 35.45 |
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.